Cibele Barbosa Carroll

Cibele Barbosa Carroll

Auto-generated profile, based on publicly available information

Cibele Barbosa Carroll

University of Wisconsin Carbone Cancer Center, Madison, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2022 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
MSMary E. Sesto
Mary E. Sesto
CCCibele B. Carroll
Cibele B. Carroll
XZXiao Zhang
Xiao Zhang
KCKaren B. Chen
Karen B. Chen
ATAbigail Terhaar
Abigail Terhaar
ATAmye J. Tevaarwerk
Amye J. Tevaarwerk

28 August 2021 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
RLRebecca P. Luoh
Rebecca P. Luoh
ATAmye J. Tevaarwerk
Amye J. Tevaarwerk
TCThevaa Chandereng
Thevaa Chandereng
ESElena M. Smith
Elena M. Smith
CCCibele B. Carroll
Cibele B. Carroll
MSMary E. Sesto
Mary E. Sesto
Background: Portals can assist patients in managing their healthcare. Understanding how patients with cancer use portals can facilitate improvements in patient engagement in cancer care. This study sought to determine if patients with cancer used portals differently for cancer versus noncancer purposes. The effects of geographic residence (rural vs. urban residence) and cancer stage on portal usage were also investigated.Methods: We conducted a retrospective analysis of portal usage by patients seen at an NCI‐designated cancer center between 2015 and 2019. Demographics, cancer characteristics, and portal usage (number of successful logins, messages sent, and results viewed) were extracted. Messages sent and results viewed in the portal were deemed oncologist‐specific and cancer specific if sent to or ordered in medical oncology departments, respectively.Results: The analysis included a total of 5950 patients with cancer. Patients were less likely to send and view oncologist‐specific messages compared to non‐oncologist‐specific messages. They were also less likely to view cancer results compared to noncancer results. Compared to urban counterparts, patients residing in rural areas had lower odds of having any logins and logged in less frequently during the year of diagnosis. Compared to patients with non‐metastatic disease, individuals with metastatic disease were more likely to become frequent portal users.Conclusions: Patients may use portals differently for cancer versus noncancer purposes; urban residence and metastatic cancer were associated with more frequent usage. Further investigation can inform interventions to increase accessibility for groups at a disadvantage related to the use of this technology and to help patients better leverage portals to manage their cancer.

1 January 2020 in Cadernos de Saude Publica
Verified
Journal Article
Open access
PDF file
CCCibele Barbosa Carroll
Cibele Barbosa Carroll
MGMarcia Gomide
Marcia Gomide
Resumo: A alta complexidade é componente fundamental da Política Nacional para a Prevenção e Controle do Câncer no âmbito do Sistema Único de Saúde (SUS) brasileiro. Tem como obrigação garantir cuidado integral aos pacientes. A regulação é parte da estrutura organizacional, sendo responsável por definir os fluxos de atendimento. No Rio de Janeiro, a Central de Regulação iniciou as atividades em junho de 2015, organizando procedimentos ambulatoriais de alta complexidade. O presente trabalho tem como objetivo analisar o deslocamento para o tratamento de pessoas com tumores digestivos no Estado do Rio de Janeiro, antes e após a atuação da regulação, sob a perspectiva da Análise de Redes Sociais (ARS). Foi desenvolvido um estudo ecológico, comparando os períodos anterior (2013) e posterior (2016) à implantação da central reguladora. A pesquisa foi desenvolvida com a utilização de dados secundários provenientes do Departamento de Informática do SUS. Desse modo, foram desenhados dois sociogramas referentes aos anos 2013 e 2016, relacionando local de residência com local de internação. Com essa abordagem foi possível identificar algumas mudanças na dinâmica das relações entre as microrregiões do estado após a implantação da regulação. As microrregiões que apresentam estabelecimentos de Alta Complexidade em Oncologia exibiram um incremento no número de internações no segundo ano estudado. Observa-se ainda que a microrregião Rio de Janeiro mantém centralidade de grau nos dois momentos. A utilização da ARS para a avaliação de políticas públicas pode trazer uma importante contribuição para planejamento e gestão em saúde.

1 June 2022 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
HEHamid Emamekhoo
Hamid Emamekhoo
CCCibele B. Carroll
Cibele B. Carroll
CSChelsea Stietz
Chelsea Stietz
JPJeffrey B. Pier
Jeffrey B. Pier
MLMichael D. Lavitschke
Michael D. Lavitschke
ATAmye J. Tevaarwerk
Amye J. Tevaarwerk
PURPOSE: Structured data elements within electronic health records are health-related information that can be entered, stored, and extracted in an organized manner at later time points. Tracking outcomes for cancer survivors is also enabled by structured data. We sought to increase structured data capture within oncology practices at multiple sites sharing the same electronic health records. METHODS: Applying engineering approaches and the Plan-Do-Study-Act cycle, we launched dual quality improvement initiatives to ensure that a malignant diagnosis and stage were captured as structured data. Intervention: Close Visit Validation (CVV) requires providers to satisfy certain criteria before closing ambulatory encounters. CVV may be used to track open clinical encounters and chart delinquencies to encourage optimal clinical workflows. We added two cancer-specific required criteria at the time of closing encounters in oncology clinics: (1) the presence of at least one malignant diagnosis on the Problem List and (2) staging all the malignant diagnoses on the Problem List when appropriate. RESULTS: Six months before the CVV implementation, the percentage of encounters with a malignant diagnosis on the Problem List at the time of the encounter was 65%, whereas the percentage of encounters with a staged diagnosis was 32%. Three months after cancer-specific CVV implementation, the percentages were 85% and 75%, respectively. Rates had increased to 90% and 88% more than 2 years after implementation. CONCLUSION: Oncologist performance improved after the implementation of cancer-specific CVV criteria, with persistently high percentages of relevant malignant diagnoses and cancer stage structured data capture 2 years after the intervention.

1 January 2023 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
HEHamid Emamekhoo
Hamid Emamekhoo
TCThevaa Chandereng
Thevaa Chandereng
MSMary E. Sesto
Mary E. Sesto
RLRebecca Luoh
Rebecca Luoh
EBElena M. Bergeson
Elena M. Bergeson
ATAmye J. Tevaarwerk
Amye J. Tevaarwerk
PURPOSE: We sought to evaluate the patterns of portal usage among patients with cancer who regularly log in to the portal. These data will inform approaches to facilitate portal use among patients with cancer. PATIENTS AND METHODS: We conducted a retrospective analysis of patient portal usage by patients with cancer at the University of Wisconsin Carbone Cancer Center. Our analysis focuses on patterns of portal use by regular users (≥ 2 portal logins/year, > 3 months) receiving ongoing oncology care between January 1, 2017, and December 31, 2019. Demographics, cancer characteristics, number of oncology visits per month, and portal usage data were extracted. Regular portal users were grouped and compared on the basis of their frequency of use. A linear mixed-effects model was used to determine if the frequency of oncology visits influenced the number of logins. RESULTS: We identified 2076 regular portal users. The median number of portal logins/year was 72 for the entire cohort. Age and race were associated with frequency of portal logins. There was no difference in frequency of portal login on the basis of cancer type or stage. Each additional oncology office visit in a month increased the frequency of portal logins by 3.05 ± 0.11 (SE) within the same month. Messages and test result functionalities were used by 98.7% and 98.9% of the regular users, respectively. Regular users who logged in to portal more frequently used all five studied portal functionalities. CONCLUSION: Patients with cancer who use portals regularly use it more in proximity to an oncology office visit and use multiple available portal functionalities. These findings can direct strategic planning to facilitate portal utilization among those not engaged with this tool.

18 March 2020 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
MTMariana Yoshii Tramontin
Mariana Yoshii Tramontin
PFPaulo Antônio Silvestre de Faria
Paulo Antônio Silvestre de Faria
CNCristina Moreira Do Nascimento
Cristina Moreira Do Nascimento
CBCibele de Aquino Barbosa
Cibele de Aquino Barbosa
MBMaria de Fátima Rei Pereira Barros
Maria de Fátima Rei Pereira Barros
DBDaniel Bulzico
Daniel Bulzico
SUMMARY Most papillary thyroid carcinomas (PTC) harbor excellent prognosis. Although rare, distant metastases normally occur in lungs and/or bones. Here we describe a rare case of pancreatic metastasis presenting with rapid onset cholestatic syndrome. A literature review was also performed. A 73-year-old man with a high risk PTC was submitted to total thyroidectomy (TT) followed by radioiodine therapy. After initial therapy, he persisted with progressive rising serum thyroglobulin levels but with no evidence of structural disease. Recently, the patient presented with a rapid onset and progressive cholestatic syndrome. A 4 cm lesion in pancreas was identified, with echoendoscopy fine-needle aspiration biopsy (FNAB) confirming a pancreatic metastasis from PTC. The patient was submitted to a successful pancreaticoduodenectomy. Pancreatic metastases of PTC are rare and few long-term follow-up data are available to guide management. Fourteen cases were former reported, mean age was 65.7 years-old with mean time between PTC and pancreatic metastasis diagnosis of 7.9 years. Nine of them had another distant metastasis, nine were diagnosed by FNAB and just two received sorafenib.